Core Insights - SOPHiA GENETICS S.A. reported a strong Q3 performance with a 23% year-over-year revenue growth, driven by new customer signings and expansion within existing accounts [4][27][40] - The company raised its 2025 revenue guidance to a range of $75 million to $77 million, reflecting confidence in continued growth momentum [3][36] Customer Growth and Expansion - In Q3, SOPHiA signed 31 new customers, bringing the total for 2025 to 94, surpassing the previous year's total of 92 [3][17] - The company successfully expanded its offerings at existing institutions, including major deals with Gustave Roussy and New South Wales Pathology [2][5] Market Performance - U.S. revenue grew by 30% year-over-year, contributing significantly to overall growth [1][15] - EMEA region saw a 24% revenue growth, with notable contributions from the UK and Belgium, which grew by 120% and 70% respectively [14][15] Product Development and Innovation - The company highlighted the success of its liquid biopsy application, MSK Access, which is gaining traction among customers [5][7] - SOPHiA introduced a new technology called SOPHiA DDM Digital Twins, aimed at enhancing treatment decision-making for oncologists [9][10] Financial Performance - Total revenue for Q3 was $19.5 million, compared to $15.9 million in the same quarter last year, with gross profit increasing to $12.9 million [27][29] - Adjusted gross margin remained strong at 73.1%, despite a significant increase in data processed by the platform [11][29] Strategic Partnerships - The partnership with AstraZeneca is expected to enhance market access for liquid biopsy testing and contribute to drug development [7][21] - Collaborations with Myriad Genetics and ADAM Innovations are aimed at developing regulated companion diagnostics in the U.S. and Japan [7][21][63] Future Outlook - The company anticipates continued growth in 2026, driven by strong customer demand and the successful implementation of new applications [36][70] - SOPHiA is focused on optimizing costs while expanding its customer base and product offerings [12][38]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [29] - Full year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [33] - Adjusted gross margin for 2025 was 74.2%, an increase of 140 basis points from 72.8% in 2024 [35] - Annualized revenue churn was less than 1% for 2025, indicating strong customer retention [34] Business Line Data and Key Metrics Changes - Excluding biopharma, clinical revenue grew 31% year-over-year in Q4 2025 [16] - Hemato-oncology testing volumes grew 27% year-over-year in Q4 2025 [18] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [19] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4 2025, with clinical revenue up 35% year-over-year [17] - North America saw analysis volumes grow 45% year-over-year in Q4 2025 [17] - Asia Pacific revenue grew 44% in Q4 2025, driven by India and Australia [18] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives to modernize its platform [9][10] - New products like MSK-ACCESS and MSK-IMPACT are expected to drive growth in 2026 [19] - The company aims to achieve adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027 [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and customer signings [43] - The company anticipates a back-half weighted growth in 2026 due to new business coming online [39] - Management noted that the biopharma sector is expected to contribute positively to revenue in 2026 [60] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [10] - The company has raised $15.5 million in net proceeds through an at-the-market facility [32] Q&A Session Summary Question: Contributions from key growth drivers for 2026 - Management highlighted the ramping of MSK-ACCESS as a significant growth driver, with strong customer signings and volumes expected to increase [46][47] Question: Net dollar retention and cross-selling strength - Management noted that net dollar retention increased to 115%, driven by low churn and strong growth across various application sets [51][53] Question: Potential annual contribution from new pharma contracts - Management indicated that while the pharma business is expected to improve, it takes time to ramp up and contribute significantly to revenue [58][60] Question: Expansion potential with large health systems - Management expressed optimism about growing accounts materially over time, with significant expansion opportunities identified [62][64] Question: Volume price mix for 2026 guidance - Management expects ASPs to increase due to higher-priced tests, while also anticipating volume growth in regions with lower ASPs [68][70] Question: New CEO's approach and potential changes - The new CEO emphasized a focus on scaling the business and unlocking the full value of the platform, while maintaining a partnership with the outgoing CEO [71][73]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [30] - Full-year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [34] - Gross profit for Q4 2025 was $14.7 million, up 21% from $12.1 million in the prior year [30] - Adjusted gross margin for the full-year 2025 increased by 140 basis points to 74.2% [36] Business Line Data and Key Metrics Changes - Clinical revenue, excluding biopharma, grew 31% year-over-year in Q4 2025 [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [19] - Platform analysis volume was over 105,000 in Q4 2025, a 16% increase from 91,000 in Q4 2024 [30] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4 2025, with clinical revenue up 35% year-over-year [17] - North America saw analysis volumes grow 45% year-over-year in Q4 2025 [17] - Asia Pacific revenue grew 44% in Q4 2025, driven by India and Australia [18] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives like Digital Twins to enhance patient care [12] - SOPHiA GENETICS aims to continue its growth trajectory by leveraging its extensive customer network and enhancing its platform [14] - The transition in leadership to Ross Muken as CEO is expected to drive the next phase of growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [44] - The company expects full-year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [40] - Adjusted EBITDA loss is projected to decrease to between $29 million and $32 million in 2026 [41] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [8] - Annualized revenue churn was at a record low of less than 1% for 2025 [35] - The company raised $15.5 million in net proceeds through an at-the-market facility [33] Q&A Session Questions and Answers Question: What contributions are expected from key growth drivers such as MSK-ACCESS and IMPACT? - Management highlighted that the ramping of MSK-ACCESS continues to be a significant driver, with sizable customers starting to come online [48][49] Question: Can you speak to the net dollar retention increase to 115% and what drove the cross-selling strength? - Management noted that the low churn rate and re-acceleration of volumes in oncology and rare disease contributed to the strong net dollar retention [52][54] Question: What is the potential annual contribution from new pharma contracts? - Management indicated that while the pharma business takes time to ramp, they expect a net positive contribution in 2026 [60][61] Question: How do you assess the potential for the two large health systems added? - Management expressed optimism about the potential for significant growth from these accounts, with opportunities for expansion in the future [63][65]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [28] - Full year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [32] - Gross profit for Q4 was $14.7 million, up 21% from $12.1 million in the prior year [28] - Adjusted gross margin for the full year 2025 was 74.2%, an increase of 140 basis points from 72.8% in 2024 [34] - Annualized revenue churn was less than 1% for 2025, with net dollar retention increasing to 115% [33] Business Line Data and Key Metrics Changes - Clinical revenue excluding biopharma grew 31% year-over-year in Q4 2025 [14] - Hemonc volumes grew 27% year-over-year in Q4, indicating strong performance in hemato-oncology testing [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [17] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4, with clinical revenue up 35% year-over-year [15] - North America saw analysis volumes grow 45% year-over-year in Q4 [15] - Asia Pacific revenue grew 44% in Q4, driven by India and Australia [16] - Latin America experienced a recovery with 49% revenue growth in Q4, particularly in Mexico and Brazil [16] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives to modernize its platform [8] - SOPHiA DDM Digital Twins were launched to create AI-driven virtual representations of patients, enhancing treatment decision-making [11] - The company aims to leverage partnerships, such as with MD Anderson, to co-develop new tests and applications [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [42] - The company expects full year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [38] - Adjusted EBITDA loss is projected to be between $29 million and $32 million for 2026, an improvement from 2025 [39] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [7] - The platform's scalability has improved significantly, allowing for faster and more cost-efficient genomic analysis [9] Q&A Session Summary Question: Contributions from key growth drivers for 2026 - Management highlighted strong performance in Q4 with 31% revenue growth and emphasized the ramping of MSK-ACCESS as a key driver for growth [46][47] Question: Net dollar retention and cross-selling strength - Management noted that the re-acceleration in net dollar retention to 115% reflects the platform's stickiness and the ability to expand within accounts [51][52] Question: Potential annual contribution from new pharma contracts - Management indicated that while the pharma business takes time to ramp, they expect a positive contribution in 2026, with ongoing strategic steps to enhance growth [58][60] Question: Expansion potential with new health systems - Management expressed optimism about the potential for significant growth with the two large health systems, indicating opportunities for expansion beyond initial applications [62][65] Question: Volume price mix for 2026 guidance - Management expects ASPs to increase due to higher-priced tests being sold, while also anticipating volume growth in regions with lower ASPs [70][71] Question: New CEO's approach and potential changes - The new CEO emphasized a focus on scaling the business and unlocking the full value of the platform while maintaining a disciplined investment strategy [73][75]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $19.5 million, a 23% increase from $15.9 million in Q3 2024, continuing a trend of accelerating growth [26][32] - Adjusted gross margin remained flat at 73.1% year-over-year, despite a 40% increase in data processed by the platform [12][28] - Adjusted EBITDA loss was $10.2 million, an 8% increase from the prior year loss of $9.4 million, indicating improved operating leverage when excluding certain charges [31][33] Business Line Data and Key Metrics Changes - The company signed 31 new customers in Q3, bringing the total for 2025 to 94, surpassing the 92 customers signed in all of 2024 [5][18] - Revenue from the US market grew 30% year-over-year, contributing significantly to overall growth [7][15] - HMONK analysis volumes grew 18% year-over-year, while liquid biopsy testing saw over 2,000 analyses conducted in Q3, marking a 300% increase year-over-year [16][26] Market Data and Key Metrics Changes - EMEA region experienced a 24% revenue growth, with the UK and Belgium growing 120% and 70% respectively [15] - Asia-Pacific saw a 35% increase in analysis volume, with Japan beginning to contribute revenue as partnerships ramp up [16][19] - Latin America showed softness, but recent booking momentum suggests potential for recovery [16] Company Strategy and Development Direction - The company is focused on expanding its customer base and increasing the adoption of its applications, particularly in the US and liquid biopsy markets [5][10] - Strategic partnerships, such as with AstraZeneca for liquid biopsy testing, are expected to enhance market access and drive future growth [10][20] - The introduction of SOPHiA DDM Digital Twins aims to leverage multimodal data for better treatment decisions, indicating a shift towards more advanced AI-driven solutions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum, citing strong customer signings and a healthy pipeline for future growth [36] - The company raised its 2025 revenue guidance to $75 million-$77 million, reflecting optimism about continued growth [32][33] - Management acknowledged challenges such as elevated social charges and foreign exchange impacts but emphasized ongoing efforts to optimize costs and maintain growth [30][33] Other Important Information - The company analyzed over 99,000 patients across 70 countries in Q3, showcasing the extensive use of its platform [12] - Total cash burn for Q3 was $13.1 million, a 36.5% increase year-over-year, but the company maintains a strong cash position of $81.6 million [31][32] Q&A Session Summary Question: Why is the Q4 growth guidance lower than Q3? - Management indicated a conservative approach to guidance, emphasizing strong momentum but wanting to ensure continued overachievement [39][41] Question: How many liquid biopsy customers are generating revenue? - Approximately 20% of the 60 liquid biopsy customers have started routine analyses, with expectations for significant ramp-up in the coming quarters [42][45] Question: What is the outlook for biopharma R&D spending in 2026? - Management expressed optimism about biopharma spending, noting a favorable position for SOPHiA in the market and strong pipeline activity [50][53] Question: How did customer onboarding times trend in Q3? - Implementation activities remained healthy, with a substantial backlog still present, indicating strong future revenue potential [74] Question: What is the expected contribution from AstraZeneca in Q4? - AstraZeneca's contributions are expected to ramp up in Q4, with revenue recognized upon hitting project milestones [60][62]

Core Insights - SOPHiA GENETICS reported a strong third quarter for 2025, with revenue growth accelerating to 23% year-over-year, marking the third consecutive quarter of growth [3][6] - The company signed 31 new customers in Q3 2025, with an average contract value increase of 180% year-over-year, indicating robust business momentum [3][7] - The adjusted EBITDA loss improved by 13% year-over-year when excluding elevated Swiss social charges on equity-based compensation, reflecting strong operational leverage [3][12] Financial Performance - Revenue for Q3 2025 was $19.5 million, up from $15.9 million in Q3 2024, representing a 23% increase [6][32] - Gross margin was reported at 66.3% and adjusted gross margin at 73.1%, compared to 67.2% and 73.1% respectively in the prior year [6][33] - The net IFRS loss was $20.0 million, a 9% increase from the previous year, while the adjusted EBITDA loss was $10.2 million, up 8% year-over-year [6][30] Business Highlights - The company performed a record 99,000 analyses on its SOPHiA DDM platform, achieving a 9% year-over-year volume growth [7] - Significant growth was noted in the U.S. market, with a 30% year-over-year revenue increase [12] - SOPHiA DDM was adopted by major institutions, including Nice University Hospital in France and Baylor Scott & White Health in Texas, expanding its application areas [7][12] Future Outlook - Full-year revenue is now expected to be between $75 million and $77 million, reflecting a year-over-year growth of 15% to 18% [6][12] - The adjusted EBITDA loss is projected to be between $39 million and $41 million for the full year, factoring in the impact of Swiss social charges and currency fluctuations [6][12] - The company aims to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [12][30]